Alectenib for ALK + cancers – pro
There is phase II evidence and some case reports supporting alectinib in advanced solid tumors with ALK mutation. In particular. Swanton reported on the effectiveness on the approach in various cancer types with ALK mutation. This drug is FDA approved for NSCLC, based on the ALK mutation, and for ALK + anaplastic lymphoma. It use off-label is supported by growing literature and at least two phase II studies.
Hitomi Sumiyoshi Okuma, Ayumu Arakawa, Akihiro Hirakawa, Shinji Kohsaka etal, Efficacy and safety of alectinib in pediatric and adult patients with ALK altered advanced solid tumors: Results from the TACKLE phase II trial, a MASTER KEY substudy (NCCH1712/MK003). Journal of Clinical Oncology Volume 43, Number 16_suppl https://doi.org/10.1200/JCO.2025.43.16_suppl.3105
Shreenivas, A., Janku, F., Gouda, M.A. et al. ALK fusions in the pan-cancer setting: another tumor-agnostic target?. npj Precis. Onc. 7, 101 (2023). https://doi.org/10.1038/s41698-023-00449-x
Swanton C, Friedman CF, Sweeney CJ, et al. Activity and safety of alectinib for ALK-altered solid tumors from MyPathway. Presented at: American Association for Cancer Research Annual Meeting 2022; April 8-13, 2022; New Orleans, LA. Abstract CT032.
Swanton C, Friedman CF, Sweeney CJ, at al. Activity and safety of alectinib for ALK-altered solid tumors from MyPathway. Presented at 2022 AACR Annual Meeting (April 8 – 13). In: Proceedings of the 113th Annual Meeting of the American Association for Cancer Research; 2021 April 8-13; New Orleans LA. Philadelphia (PA): AACR; 2022. Abstract nr CT032.